GW679769
Phase 2Small molecule
GSKGW679769 is one of 228 small molecule programs targeting Dyspepsia. It is currently in Phase 2.
8
Indications
18
Total Trials
0
Active Trials
227
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
386 competitors in Major Depressive Disorder
#DrugCompanyPhaseTrials
1Elavil
AstraZenecaPhase 3
Ketalar
Boehringer IngelheimPhase 3
Comparator: Pbo
Merck & Co.Phase 3
Psilocybin
COMPASS PathwaysPhase 3
Fetzima
AbbViePhase 3
Levophed
GGeneral Hospital of Ningxia Medical University
Phase 3
SPD489
TakedaPhase 3
Vraylar
AbbViePhase 3
CYB003
CCybin IRL Limited
Phase 3
GW679769
GSKPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Insomnia4 trials
Nausea and vomiting3 trials
Major Depressive Disorder2 trials
Overactive Bladder2 trials
6 more indications
Nausea1 trial
Observational Study1 trial
Dyspepsia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GW679769. EMBL-EBI & Wellcome Sanger Institute.
- [4]